Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCentene Ambetter formulary Coverage & PA | OpenPay…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCentenePolicy N/A

    Ambetter Health Formulary (Prescription Drug List) — Coverage Criteria

    Customize your policy alerts

    Sign up for all Centene policy alerts

    Know when Centene releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines the Ambetter Health prescription drug formulary, tiering, coverage designations (PA, ST, QL, NF, SP) and prior authorization/coverage processes for Ambetter prescription drug benefits.

    Policy Summary
    PayerCentene | Ambetter Health
    PolicyAmbetter Health Formulary (Prescription Drug List) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes in this revision
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit a completed Prior Authorization form with required documentation; urgent PA requests responded to within 24 hours and non-urgent within 72 hours.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Tier 0–4Formulary copay tiers described
    7-dayOpioid new starts limits
    QL presentQuantity limits present
    PA presentPrior authorization flagged
    Jan 2026Document update stamp

    Formulary Coverage Rules and Criteria

    Formulary coverage rules

    Formulary coverage and tiering

    Formulary tiering and preferred drugs: Generics are preferred as first-line when available; preferred brand-name drugs are listed on Tier 2 when generics are not suitable.

    Tier definitions described in document

    Specialty drugs: Tier 4 is the specialty tier for high-cost or complex chronic therapies and may require fulfillment at participating specialty or hemophilia network pharmacies.

    Specialty network and handling described in formulary guidance

    Non-formulary drugs and exceptions: Non-formulary products are not covered unless an exception is approved via prior authorization; alternative medications are listed adjacent to non‑covered products.

    Providers must submit a PA form to request an exception

    Policy Summary
    PayerCentene | Ambetter Health
    PolicyAmbetter Health Formulary (Prescription Drug List) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes in this revision
    Effective DateJan 1, 2026
    Next Review DateN/A
    Key ActionSubmit a completed Prior Authorization form with required documentation; urgent PA requests responded to within 24 hours and non-urgent within 72 hours.
    SourceLink
    On This Page
    Formulary Coverage Rules and CriteriaFormulary Modifiers, Limits, and Coding ExamplesPrior Authorization, Step Therapy, and Documentation RequirementsInitial Therapy Limitations and RequirementsContinuation Therapy and Refill ControlsStep Therapy Sequences and IndicatorsQuantity and Fill Limits by ProductSpecialty Pharmacy, Infusion, and Fulfillment RequirementsAbbreviations and Term DefinitionsPolicy Background and ScopeBiosimilar Listings and Notes

    Opioid supply limits

    Opioid prescribing limits for new starts

    Opioid new-start quantity limits: New opioid starts are limited to a 7-day supply. The formulary allows up to two 7-day fills during any 28-day period and up to 28 non-consecutive days of supply in any 90-day period; supplies beyond these limits require prior authorization.7-day supply; max 2 fills/28 days; up to 28 non-consecutive days/90 days

    Limit applies cumulatively to all opioid prescriptions

    Biologic products (adalimumab examples)

    Covered when listed formularies with limits and PA are satisfied

    Adalimumab and biosimilars: Adalimumab presentations (including listed biosimilars) are covered when prior authorization is approved and package/quantity limits are met (examples include QL(0.143 EA daily) and package/max fill limits per 180 days).QL(0.143 EA daily); package/max fill per 180 days

    Multiple adalimumab presentations list PA and QL

    PDE4 inhibitors and selected oral agents

    Covered when PA and quantity/age rules satisfied

    Otezla and PDE4 inhibitors: OTEZLA (PDE4 inhibitor) is covered subject to prior authorization and quantity limits (ILimits = QL(2 EA daily)); certain packaged forms also include age limits (e.g., AL: At least 45 yrs old up to 79 yrs old) and package fill restrictions.QL(2 EA daily); AL(45-79 yrs) where specified; package limits per 180 days

    Age and package limits apply as shown on product lines

    Opioid and analgesic product coverage

    Covered with formulary-specific limits and prior authorization where indicated.

    Opioid product coverage rules: Opioid and analgesic products are assigned tiers and product‑level ILimits; many entries indicate new‑start 7‑day limits and per‑product QL (e.g., QL values shown per formulation). Select opioid products or formulations require prior authorization (PA) as noted.See per‑product QL and PA flags

    Adherence to per‑product ILimits and PA required for coverage

    Formulary tiering and administrative conditions

    Formulary coverage is expressed via tier assignments and administrative flags; coverage is contingent on plan tier and any PA/SP requirements.

    Tier coverage: Drugs are assigned to tiers (examples include Tier 0, 1A, 1B, 2, 3, 4); tier determines member cost-sharing and access rules per plan.

    Tier definitions and examples are provided in the formulary key

    Administrative flags (PA/ST/SP/QL): Coverage is governed by administrative flags shown on each line: PA (prior authorization), ST (step therapy), SP (specialty), QL (quantity limit), and AL (age limit). Adherence to these flags is required for coverage as specified per product.

    PA/ST/SP/QL appear on product ILimits fields throughout the listing

    Product-level coverage controls

    Coverage listed per product line with tier and ILimits; PA and QL determine access controls

    Formulary line requirements: Individual product entries include tier assignment and ILimits (quantity limits) and may include PA or SP; coverage requires adherence to those ILimits and prior authorization where indicated.Refer to ILimits values on product lines

    This extract lists ILimits but does not include patient‑specific clinical criteria

    Coverage conditions (by tier/limit flags)

    Formulary coverage and limits apply as listed; coverage varies by tier and product-specific flags (PA, ST, QL).

    Formulary tier and limits: Coverage and patient access require adherence to tier assignment, quantity limits, and any PA/ST flags shown for each product line.

    See individual product lines for specific QL, PA, and ST values

    Indication-limited antimalarial coverage

    Examples of indication-limited coverage

    Antimalarial coverage limited to malaria treatment: Certain antimalarial combinations (e.g., atovaquone-proguanil, COARTEM) are covered for malaria treatment only and are limited to one fill per specified interval with defined QL per fill (e.g., QL(12 EA per fill) for atovaquone-proguanil; limit 1 fill per 180 days where noted).Limit 1 fill per 180 days; QL as specified (e.g., 12 EA per fill)

    Documentation of indication (malaria treatment) required for coverage

    PA/SP managed products

    Utilization management for select anti-infectives and antineoplastics

    PA/SP required for select agents: Multiple anti‑infective and antineoplastic agents are designated SP and/or PA; prior authorization (and specialty program handling for SP) is required for coverage as noted on the product line.PA/SP as noted per product

    Failure to obtain required PA/SP may result in denial

    Formulary tiering and utilization controls

    Coverage governed by formulary tiering and utilization management flags

    Tier and utilization controls: Drugs are assigned tiers (e.g., 1B, 3, 4) and may have quantity limits (QL) and require prior authorization (PA) or special program (SP). Coverage is subject to those controls as indicated for each line‑item.

    No explicit clinical AND/OR criteria present in this segment; adhere to ILimits and PA/SP flags

    The formulary provided in this extract is a representation of Ambetter Health’s Prescription Drug List but is not a complete list of covered drugs. The document itself notes that not all dosage forms or strengths may be covered, and that specific plan benefit designs can restrict coverage even for items that appear on the formulary. Providers and billing staff should verify member-specific benefit plans for exact coverage, tier assignment, and member cost-sharing before assuming coverage.

    This partial extract does not include explicit exclusion statements. The listing shows product lines, tier assignments and ILimits (e.g., QL, AL, PA) but contains no standalone exclusion language in the cited portion. Absence of exclusions in this excerpt does not imply there are none in the full policy — check the complete policy for formal exclusion rules.

    In the portions of the formulary shown here there are no explicit exclusion rules stated. The extract lists product-level tiers and quantity limits (for example, several NSAID entries include QL values) but does not present named exclusion criteria within these chunks.

    No explicit clinical exclusions are provided in this excerpt. The cited lines list multiple testosterone and related products with tier and ILimits information but do not define clinical exclusion criteria or specific medically ineligible conditions in the presented text.

    The extract segments reviewed do not contain explicit exclusion language. Entries in this area focus on product presentations, tiers, and ILimits (e.g., PA for certain pen or penfill products) rather than naming conditions or services that are excluded from coverage.

    This is a partial extract of the formulary and therefore does not list all products. The text notes that products not present in these chunks are outside the scope of the provided excerpt; reviewers should consult the full formulary for comprehensive product listings and any product‑specific coverage rules.

    No explicit exclusion rules are present in the chunks cited here. The segment contains tiering, QL, PA and SP flags for drug lines (e.g., verapamil and digoxin entries) but does not state standalone exclusion provisions in this portion of the document.

    For digestive enzyme products such as ZENPEP (and similarly CREON in other portions of the formulary), the extract specifies that non‑FDA approved uses require Prior Authorization (PA). Prior authorization is therefore required to cover off‑label or non‑FDA indications for these enzyme products.

    The partial extract does not include statements declaring items as 'not medically necessary.' The cited lines contain tier, ILimits and PA flags for listed products but no explicit 'not medically necessary' determinations in this excerpt.

    The portions of the document shown here do not contain any explicit 'not medically necessary' language. Product entries in this area focus on quantity limits and tiering without issuing formal non‑coverage declarations for specific clinical scenarios.

    No 'not medically necessary' findings are present in the provided excerpt. The content in these chunks addresses formulary structure (tiers, ILimits) and product entries rather than formal determinations of medical necessity.

    This extract does not state any 'not medically necessary' conditions. The referenced material lists products, associated ILimits and PA indicators but does not include explicit NMN rulings in the visible segments.

    No explicit 'not medically necessary' statements are present in these chunks. The anti‑infective and related entries specify QL per fill and tiering, but do not contain stated NMN determinations in the excerpt.

    This item is an unspecified summary fallback present in the inventory with no content provided in the extract. Refer to the complete formulary for any missing summary or policy statement related to this inventory line.

    Formulary Modifiers, Limits, and Coding Examples

    Formulary modifiers and limitsmixed
    QL(1 EA daily)Quantity limit examples listed for multiple products
    AL(At least yrs old)Age limit examples (various entries show age limit placeholders)
    PAPrior Authorization requirement marker
    STStep therapy requirement marker
    SPSpecialty tier marker
    Formulary quantity/package limits (examples)mixed
    QL(0.143 EA daily)Quantity limit example shown for multiple adalimumab presentations
    package(s) per 180 day(s) retailPackage/fill limit example
    Additional formulary limits and age limitsmixed
    QL(2 EA daily)Quantity limit example (e.g., OTEZLA tabs)
    AL(At least 45 yrs old Up to 79yrs old)Age limit applied to OTEZLA entries
    No billing codes listed in this extractmixed
    No codes listed
    Quantity limit examplesmixed
    QL(900 ML per 30 day(s) retail)Quantity limit for rivaroxaban suspension (rivaroxaban SUSR 1 MG/ML)
    QL(2 EA daily)Quantity limit for rivaroxaban tablets 2.5 mg
    Additional QL entriesmixed
    QL(4 ML daily)Quantity limit example (example: arformoterol tartrate)
    QL(0.38 GM)Quantity limit example for BREZTRI AEROSPHERE
    QL for oral productsmixed
    QL(4 EA daily)Quantity limit example for alprazolam 0.25-1 mg tablets
    QL(8 ML daily)Quantity limit example for diazepam oral solution
    NDC-like strength references and solution concentrationsmixed
    0.4 MG/ML, 4 MG/10MLnaloxone hcl SOLN strengths referenced as product names (formatted as in document)
    Example drug entriesmixed
    XIFAXAN 200 MGlisted with Tier = 3 and ILimits = QL(3 EA daily)
    Formulary utilization codesmixed
    QL(4 EA daily; 40 EA per fill retail)Quantity limit for minoxidil 2.5 MG, 10 MG (and other entries)
    QL(300 ML per fill retail)Quantity limit for unspecified anti-infective liquid
    PAPrior authorization required (multiple entries)
    SPSpecialty designation (appears on several antineoplastic entries)
    Antimalarial limitsmixed
    QL(12 EA per fill retail; 12 per fill mail)Quantity limit for atovaquone-proguanil hcl
    1 max fill(s) per 180 day(s) retailFill frequency limit for malaria treatment products
    Antineoplastic quantity limitsmixed
    QL(2 EA daily)Quantity limit example for XTANDI 80 mg / other entries
    Quantity Limits (examples)mixed
    QL(1 EA daily)Quantity limit example
    QL(2 EA daily)Quantity limit example
    QL(75 ML)Quantity limit for HEMANGEOL SOLN PO (example line-item)
    Opioid new-start supply limits — key facts
    New-start supply limitNew opioid starts limited to a 7-day supply
    28-day ruleAllows up to two 7-day fills during any 28-day period
    90-day ruleAllows up to 28 non-consecutive days of supply in any 90-day period
    Exception processSupplies exceeding these limits require prior authorization
    Age limits — summary
    Example age rangeAt least 45 yrs old up to 79 yrs old
    Topical/other age limitsCommon topical agents list 'At least 12 yrs old' or 'At least 2 yrs old' where specified
    Coverage dependencyCoverage requires member age to fall within AL range shown on product line
    Age limit example (45–79 yrs)
    Concrete exampleOTEZLA entries specify AL: At least 45 yrs old Up to 79 yrs old
    ImplicationProduct will be covered only for members whose age falls within the stated range
    DocumentationAge eligibility may be documented during PA or claims processing
    Common new-start supply limit
    Standard new-start limitNew starts commonly limited to a 7‑day supply
    Applies toMany opioid products listed with 'New starts limited to 7 day supply' notation
    Provider actionDocument justification and seek PA for longer initial supply
    Sample QL thresholds
    Example QL (liquid inhaler)QL(4 ML daily)
    Example QL (syrup)QL(6 ML daily)
    Example QL (suspension)QL(900 ML per 30 day(s))
    Quantity limit examples
    Tablet per-day examplesQL(2 EA daily); QL(1 EA daily); QL(4 EA daily)
    Per-fill examplesQL(45 EA per fill); QL(60 EA per fill)
    Combination examplesCommon expressions used in document: per day, per fill, per 30/90/180 days
    Common quantity limits (tablets, liquids)
    Common per-day tablet limitsQL(4 EA daily); QL(6 EA daily)
    Liquid per-fill limitsQL(300 ML per fill retail)
    Most actionable examplesPer-product QL shown on ILimits governs claim adjudication
    hydroxychloroquine sulfate 400 MG — QL example
    Producthydroxychloroquine sulfate 400 MG
    Quantity limitQL(1 EA daily)
    TierTier = 1B (as listed)
    ZOLADEX 10.8 MG — QL example
    ProductZOLADEX 10.8 MG
    Quantity limitQL(0.0119 EA daily)
    Authorization flagsListed with SP; PA in formulary lines
    Examples of QL values
    Per-day tablet QLsQL(6 EA daily); QL(9 EA daily); QL(2 EA daily)
    Per-fill/volume examplesQL(75 ML per fill for select liquids)
    Practical noteDocumented QL units may be in EA, ML, GM or package/per time-period formats
    Quantity limits examples (gm/ml/day)
    Topical weight/volume QLsQL(3.5 GM daily); QL(15.15 GM daily); QL(12.9 GM daily)
    Small-volume topical QLsQL(0.29 ML daily); QL(0.082 ML daily)
    Key actionAdhere to per-day/per-fill topical QLs and fill-frequency limits (e.g., limit 1 fill per 180 days)
    Example quantity limits — topical
    Topical QL examplesClotrimazole CREA: QL(4.5 GM daily); Limit 1 Fill per 180 days
    Econazole nitrate CREAQL(85 GM per fill mail); Limit 1 Fill per 180 days
    Practical reminderSome topicals combine daily QL with max fills per 180 days — both limits apply

    Prior Authorization, Step Therapy, and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior Authorization Required for Non‑Formulary Drugs: Providers must complete and submit the payer's Prior Authorization form when requesting coverage for non‑formulary (NF) drugs. Urgent PA requests will be responded to within 24 hours of receipt of all necessary information; non‑urgent requests within 72 hours unless state law requires faster response. If disapproved or incomplete, the notice will explain specific reasons or identify missing information needed to complete the request.

    • Submit completed Prior Authorization form and supporting clinical documentation
    • Urgent requests: response within 24 hours once all information received
    • Non‑urgent requests: response within 72 hours once all information received
    Prior Authorization

    PA and Package / Quantity Limits

    PA and package/quantity limits: Many biologic and specialty products have package, fill-frequency, and quantity limits (QL) and require prior authorization. Examples include multiple adalimumab formulations with package limits per 180 days and QL entries; new starts for some injectables limited to 7‑day supplies. Exceeding QLs or not obtaining PA may result in claim denials.

    • Adalimumab products: package limits and PA (example: package(s) per 180 days retail/mail; QL listed)
    • Enbrel/Actemra examples: QL and new‑start 7‑day supply limits
    • Document intended quantity and dosing when submitting PA to reflect package/QL requests
    Prior Authorization

    PA and Age Limits

    PA and Age‑Limit Requirements: Several products require prior authorization and have age limits (AL). Verify patient age against the AL entry before submitting a PA; prescriptions not meeting age limits are at risk for denial.

    • OTEZLA: PA required; AL entries specify age ranges (e.g., At least 45 yrs up to 79 yrs)
    • Topical acne agents (benzoyl peroxide, clindamycin combinations): AL frequently specified (At least 12 yrs old)
    • Include patient age in PA documentation to demonstrate compliance with AL
    Prior Authorization

    PA for Specific Formulations

    PA Required for Selected Formulations: Specific formulations (topical foams/gels, injectables, concentrated solutions) are flagged for prior authorization. Check the formulation-level ILimits/Drug Requirements before dispensing.

    • Clindamycin topical FOAM/GEL/LOTION: AL and PA indicated for some formulations
    • Calcitriol and calcipotriene solutions: QL and PA indicated
    • Certain inhalation/solution formulations (e.g., amiodarone 150 mg/3 mL) list PA
    Prior Authorization

    Products Marked PA / SP

    Products Requiring Prior Authorization: Many individual agents and classes are explicitly marked PA or SP;PA in the formulary extract. Specialty (SP) and Tier‑4 products commonly require PA and may also require specialty pharmacy (SP) fulfillment.

    • Antineoplastics and adjunctive therapies: multiple agents flagged SP; PA (e.g., cisplatin, busulfan, carmustine)
    • Biologics and monoclonal antibodies: examples include Ruxience, Truxima, Yervoy, Arzerra marked SP; PA
    • Pulmonary vasodilators and prostacyclin agents: PA and QL entries present
    Prior Authorization

    PA for High‑Tier and Specialty Agents

    PA Required for Specified Agents and High‑Tier/Specialty Drugs: High‑tier and specialty agents (e.g., COSENTYX, REPATHA, TYVASO kits, rivaroxaban suspensions) are listed with PA and QL constraints; prescribers should request authorization and note specialty fulfillment requirements where indicated.

    • REPATHA: Tier 4 with QL and PA
    • COSENTYX formulations: QL and PA listed for multiple presentations
    • TYVASO refill kits and starter kits: PA required
    Prior Authorization

    PA for Topical Products

    Prior Authorization for Selected Topicals: Several topical agents require PA, have quantity or fill limits, and may include age restrictions. Confirm AL/QL and request PA when required to avoid denials.

    • Clindamycin phosphate combinations (e.g., clindamycin‑benzoyl peroxide, clindamycin‑tretinoin): AL and PA may apply
    • Ketoconazole, luliconazole, naftifine topical formulations: many entries show PA or QL constraints
    • Topical corticosteroids and enzyme topicals (e.g., SANTYL): PA appears in ILimits
    Note

    PA and Specialty Pharmacy Flags

    Prior Authorization Flags and Specialty Pharmacy Indicators: Formulary entries use ILimits flags such as PA, SP, ST, AL, and QL. SP indicates specialty pharmacy/network requirements; combined SP;PA or PA without SP both require authorization prior to coverage.

    • PA flag: authorization required before claim adjudication
    • SP flag: specialty fulfillment — may require dispensing through designated specialty pharmacy
    • Combined flags (SP;PA): both specialty distribution and authorization are required
    Denial Risk

    Denial Risk — QL, PA, and Step Therapy

    Denial Risk from QL, PA, and ST: Requests exceeding quantity limits, lacking required prior authorization, or not meeting step‑therapy (ST) requirements are at increased risk for denial. Prescribers should document clinical rationale, prior trials, and intended quantity to support approvals.

    • Quantity limits (QL): follow per‑day, per‑fill, and per‑period QL values shown (examples: QL(0.143 EA daily); max fills per 180 days)
    • Step Therapy (ST): where ST is listed, document prior trials of preferred agents (e.g., 'Must try ibuprofen' noted near Actemra)
    • Incomplete PA requests: denials will identify missing material information; include dosing, duration, prior therapies, and age where applicable
    Documentation Required

    Documentation to Support PA

    Documentation Requirements for Prior Authorization: When requesting PA include supporting clinical documentation — diagnosis, indication, prior medication trials (for ST), dosing, intended quantity/fill frequency, and patient age when AL applies. Incomplete requests will delay review or result in denial.

    • Include diagnosis and indication and confirm whether requested use is FDA‑approved or off‑label (non‑FDA uses often require PA)
    • Provide prior therapy history when ST applies and dates/duration of trials
    • Specify dosing, quantity requested, and package size to match formulary QL/package constraints
    Billing Rule

    Quantity and Fill Limits

    Quantity & Fill Limits — Operational Notes: Observe per‑day, per‑fill, and per‑period limits and report the requested quantity on the PA form. New‑start supply limits (e.g., 7‑day limits for certain injectables) and max fills per 30/90/180 days are enforced.

    • New starts: examples where new starts are limited to 7‑day supply (ENBREL entries)
    • Max fills: many entries list '1 max fill(s) per 180 day(s)' or similar limits — include intended refill schedule in PA
    • Package limits: biologics often list 'package(s) per 180 day(s) retail/mail' — ensure request aligns with package rules
    Prior Authorization

    PA for Non‑FDA Uses

    Non‑FDA Uses Require Prior Authorization: Digestive enzyme products (CREON, ZENPEP) and other agents list 'Non‑FDA approved uses require Prior Authorization.' For off‑label indications, include rationale and supporting literature or chart notes with the PA request.

    • CREON and ZENPEP: Non‑FDA approved uses noted as requiring PA
    • For off‑label use include clinical justification, prior treatments, and relevant diagnostics
    Step Therapy

    Step Therapy / Trial Requirements

    Step Therapy and Trial Requirements: Step therapy (ST) is applied to some drug classes and combination products. Where ST is indicated, document that required first‑line agents were tried and were ineffective, contraindicated, or not tolerated before requesting the next‑line agent.

    • ST examples: 'Must try ibuprofen' near Actemra entries; topical acne product ST entries (e.g., clindamycin‑tretinoin)
    • Therapeutic‑class preferences and tiering may imply preferred agents even where explicit ST sequence is not shown — include prior regimen details
    Step Therapy

    Step / Age / Specialty Indicators

    Step Therapy, Age‑Related and Specialty Program Indicators: Some products require both step therapy and meet age limits or specialty program requirements. Verify all applicable flags (ST, AL, SP, PA) and include evidence of meeting each criterion in the PA submission.

    • OTEZLA: ST and AL present for some package forms — include age and prior trials
    • Topical acne agents: ST plus AL (At least 12 yrs) — document prior topical treatments and patient age
    • Specialty program indicators (SP) often accompany PA for agents used in specialized care settings

    Initial Therapy Limitations and Requirements

    Initial therapy limits

    Initial therapy limitations present in extract

    Initial opioid prescriptions: New starts for many opioid products are limited to a 7‑day supply; initial fills beyond this limit require prior authorization and documentation to support a longer initial supply.7‑day new start limit

    Provider should document justification on PA requests for longer initial supply

    Initial coverage controls

    Initial dispensing controls shown via tiers and QL

    Tier/QL/PA for initial coverage: Initial coverage and dispensing are controlled by tier assignment and ILimits on the product line; initial fills must adhere to QL and require PA when indicated.See ILimits per product

    This extract does not provide patient‑specific eligibility criteria

    Step therapy indicators

    Some combination products are subject to step therapy or preferred first-line agents.

    Step therapy requirement: Products flagged 'ST' require trial and failure or intolerance of preferred agents before coverage of the non‑preferred or combination product is allowed.

    See specific product lines for ST flag and required prior therapy

    Topical acne initial therapy constraints

    Step therapy and age limits noted for topical acne agents

    Topical acne initial use: Topical acne agents commonly include age limits (e.g., AL: At least 12 yrs old) and some require step therapy (ST) before higher‑tier products will be covered.AL(At least 12 yrs)

    Examples include clindamycin phosphate combinations and DIFFERIN LOTN

    Continuation Therapy and Refill Controls

    Continuation therapy notes

    Continuation rules observed in extract

    Continuation limitations: Continuation of chronic opioid or specialty therapies is subject to ongoing quantity limits and prior authorization for continued fills; initial new‑start limits (e.g., 7 days for opioids) imply longer maintenance supplies require authorization and adherence to per‑product QL/PA rules.QL and PA per product

    Exact continuation criteria are not fully detailed in this partial extract

    Step Therapy Sequences and Indicators

    ProductST
    lisdexamfetamine dimesylate CAPS
    dextroamphetamine sulfate TABS
    methylphenidate (various formulations)
    ContextRequirement
    Actemra SOLN 80 MG/4ML (Actemra entries)
    {"text":"Must try ibuprofen before coverage ("Must try ibuprofen" noted in Actemra line)","status":""}
    ProductPrerequisite / Age Limit
    OTEZLA TABS
    QL(2 EA daily); AL(At least 45 yrs old Up to 79yrs old); PA
    SegmentST requirement
    Selected respiratory / cardiovascular combinations (examples)
    No explicit step therapy sequences listed; tiering/QL indicated rather than ST
    ProductST
    eslicarbazepine acetate 200/400/600 MG
    gabapentin (selected strengths)
    Therapeutic class / productPreference / ST note
    DPP-4 / Incretin / SGLT2 class listings (e.g., JANUMET, JARDIANCE)
    Class-based preferences implied; explicit step-failure rules not provided in extract
    Combination productST
    amlodipine-valsartan (combination)
    amlodipine-valsartan-hydrochlorothiazide
    Chunk / areaStep therapy presence
    Cardiac glycosides / verapamil and related entries
    No explicit ST rules present; tiering and PA/QL imply preference controls
    Topical acne productST
    clindamycin phosphate- tretinoin
    DIFFERIN LOTN
    ProductNotes (QL/PA)
    brimonidine tartrate (topical)
    QL(1 GM daily); PA noted for some formulations

    Quantity and Fill Limits by Product

    Various stimulants and other listed products — QL examples
    Stimulant tablet QLsExamples include QL(1 EA daily), QL(2 EA daily), QL(3 EA daily)
    Patch/large-fill QL exampleQL(280 ML per 56 day(s) retail) for certain formulations
    Operational notePer-product ILimits on the formulary determine dispensing quantity and may require PA if exceeded
    Opioids (new starts) — new-start and permitted fills
    Initial fill ruleNew opioid starts limited to a 7-day supply
    Fill frequency constraintsUp to two 7-day fills in any 28-day period; up to 28 non-consecutive days in any 90-day period
    Authorization for excessPrescribers must request prior authorization for fills exceeding these rules
    adalimumab presentations (example) — QL & package limits
    Example presentation limitsAdalimumab presentations show QL(0.143 EA daily) and package limits per 180 days
    PA requirementMany adalimumab variants list PA alongside QL/package limits
    Max-fill example1 max fill(s) per 180 day(s) retail appears for some presentations
    OTEZLA TABS — QL example
    ProductOTEZLA TABS
    Quantity limitQL(2 EA daily)
    Associated rulesSome OTEZLA pack presentations have AL: At least 45 yrs old Up to 79 yrs old and package limits per 180 days
    oxaprozin / other NSAIDs — QL examples
    NSAID QL examplesoxaprozin and related NSAIDs list examples such as QL(6 EA daily)
    VariabilityQLs vary by agent and strength as shown per-line in formulary
    Processing noteClaims exceeding QL may be denied without PA
    Multiple opioid and non-opioid products — assorted QL examples
    Assorted QL examplesExamples across opioid and non-opioid lines include QL(6 EA daily); QL(0.286 ML daily); product-specific values
    Per-unit formatsQLs expressed in EA, ML, GM, or package-per-period formats
    Claim impactExceeding the ILimits can trigger PA requirement or denial
    OTEZLA TBPK — package limits & max fills per 180 days
    Package limitOTEZLA TBPK: 1 package(s) per 180 day(s); max fill(s) per 180 day(s)
    Age limitAL indicated for some pack forms (At least 45 yrs old Up to 79 yrs old)
    Coverage notePackage and per-period max fills enforce long-term dispensing limits
    budesonide (intrarectal) — QL example
    Productbudesonide (intrarectal)
    Quantity limit3.2 GM daily
    Formulary notePer-day QL shown on ILimits governs retail and mail fills
    nitroglycerin (intra-anal) — QL example
    Productnitroglycerin (intra-anal)
    Quantity limit2 GM daily
    Processing noteAdhere to daily gram-based QL when adjudicating claims
    alprazolam tablets — QL example
    Productalprazolam tablets (0.25-1 mg)
    Quantity limitQL(4 EA daily)
    Coverage implicationPer-day QL applies across strengths listed
    albuterol syrup — QL example
    Productalbuterol syrup
    Quantity limitQL(6 ML daily)
    Claim noteLiquid QLs often expressed in mL per day or per fill
    Assorted injectable/liquid QL examples (insulin, enoxaparin, fondaparinux)
    Insulins & concentrated liquidsExamples include QL(1.34 ML daily) for some insulin products and large-volume QLs for suspensions
    Anticoagulants (enoxaparin/fondaparinux)Examples: QL(2 ML daily); QL(1.2 ML daily; 30 Day limit); QL(7.2 ML per 180 day(s) retail)
    Practical guidanceFollow per-strength ILimits on formulary lines for injectable/complex products; SP/PA flags may apply
    Selected product QL examples (fondaparinux, EPIDIOLEX, topiramate)
    Fondaparinux exampleQL(7.2 ML per 180 day(s) retail; 7 ML per 180 days mail)
    EPIDIOLEXQL(6 EA daily); PA
    TopiramateQL(8 EA daily) for some strengths
    Insulin products — QL examples
    Insulin exampleQL(1.34 ML daily) noted for some insulin-related entries
    Starter packs & devicesSome starter packs have max-fill or PA requirements noted in ILimits
    Processing noteAdhere to QL units when adjudicating insulin pens and supplies

    Specialty Pharmacy, Infusion, and Fulfillment Requirements

    Billing Rule

    Use Ambetter specialty/hemophilia network pharmacies for SP items

    Specialty tier drugs may require fulfillment at pharmacies participating in Ambetter's specialty or hemophilia networks; providers should direct prescriptions to the appropriate specialty pharmacy network when 'SP' is indicated.

    • When 'SP' is shown, use Ambetter specialty/hemophilia network pharmacies for dispensing
    • Confirm pharmacy network participation via Ambetter's pharmacy information resources
    Billing Rule

    Obtain PA and coordinate infusion‑site billing for IV products

    IV products listed with PA and QL flags (e.g., QUZYTTIR SOLN IV) may require infusion‑site billing and prior authorization; providers should coordinate authorization and site‑of‑care billing prior to administration.

    • Obtain PA for IV preparations before infusion
    • Coordinate infusion‑site authorization and appropriate billing codes
    Prior Authorization

    Apply same PA and package/QL rules to SIMLANDI (adalimumab) as HUMIRA

    SIMLANDI (an adalimumab product) is listed alongside HUMIRA with PA and package/QL rules; providers must follow the same PA and package/quantity limits for listed adalimumab products and biosimilars.

    • Treat SIMLANDI entries like HUMIRA for PA and package/QL compliance
    • Include package/QL details and obtain PA when required for adalimumab products

    Abbreviations and Term Definitions

    Formulary / Prescription Drug List — definition & abbreviations
    Definition — FormularyFormulary / Prescription Drug List: list of brand and generic drugs covered under benefit
    Abbreviations (key)PA = Prior Authorization; ST = Step Therapy; QL = Quantity Limit; NF = Non-Formulary; SP = Specialty; SF = Split Fill; AL = Age Limit
    QL meaningQuantity Limit — maximum permitted quantity per time period as indicated (e.g., 'QL(4 ML daily)')
    Formulary abbreviations and key definitions
    PA (Prior Authorization)Prior Authorization — your provider must request approval from Ambetter before some drugs will be covered
    ST (Step Therapy)Step Therapy — must try certain drugs first before another drug is covered
    QL (Quantity Limit)Quantity Limit — maximum units per day or per fill as listed (e.g., QL(2 EA daily), QL(300 ML per fill))
    QL — quantity limit definition
    QL definitionQuantity Limit — specified maximum units per day or per fill as listed (examples in document: QL(0.286 ML daily); QL(4 EA daily))
    Expression formatsQL values expressed as per-day (EA/ML/GM) or per-fill/per-period (per 30/90/180 days)
    Operational effectClaims exceeding QL may be denied or require PA as indicated
    PA — prior authorization definition and provider actions
    PA submission requirementProviders must complete the Prior Authorization form and supply necessary information for processing
    Response timesUrgent requests: response within 24 hours; non-urgent: response within 72 hours (unless state law requires faster)
    Denial noticeIf disapproved, the notice will explain reasons or identify missing information

    Policy Background and Scope

    Background: The formulary differentiates between generic and brand products and directs that generics are preferred as first‑line treatment when available. It also indicates that specialty or high‑cost products may be managed differently (e.g., specialty fulfillment or program handling), and that tiers plus administrative flags (PA, ST, QL, SP) are used to govern access and coverage.

    Biosimilar Listings and Notes

    Note